DBV Technologies Plans Strategy For Peanut Allergy Debut In U.S.
This article was originally published in The Pink Sheet Daily
The French biotech will set out its stall first in the U.S., where peanut allergy is a major concern, and plans to tackle the life-threatening condition with its transdermal patch without relying on local partners.
You may also be interested in...
With the sizeable investment, Nestlé Health Sciences also gets a three-month right of first negotiation for licensing or partnering to develop any Aimmune candidates, including Phase III AR101 for peanut allergy.
Peanut Allergy Targeted By DBV Technologies As It Raises $55 Million In Second Euro Biotech IPO This Year
France's DBV Technologies lists on NYSE Euronext in Paris and targets peanut and other food allergies for the first clinical studies of its epicutaneous patches as allergy desensitization therapies.
EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.